MarketPeel
Insider Trading Intelligence
DL

Daniel D. Long

SEPN
SVP, DRUG DISCOVERY · SEPTERNA, INC. · CIK 0002040349
FILING MIX · LIFETIME38%/62%
BUYS
5
SELLS
8
TOTAL VALUE
$800.9K
COMPANIES
1
ACTIVE SINCE
Aug 2025
HOLDINGS NOW
97,645
AVG SELL PX
$32.53
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Daniel D. Long, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+19.56%-2.31%+21.87%+21.87%
14d1+0.00%+57.51%-1.86%+59.38%+59.38%
30d1+0.00%+41.66%+0.90%+40.76%+40.76%
60d1+0.00%+39.78%+1.85%+37.93%+37.93%
90d1+0.00%+46.91%+1.84%+45.07%+45.07%
180d1+0.00%+31.88%+8.24%+23.63%+23.63%
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SEPN · 97,645 shares · as of Jul 1, 2026
027,85355,70683,559111,4122026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2026
2026
2026
FLOW · 5 buys / 8 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SEPN
SEPTERNA, INC.
SALE
SVP, Drug Discovery
3,3337,043Jul 1, 2026Jul 2, 2026View →
SEPN
SEPTERNA, INC.
PURCHASE
SVP, Drug Discovery
3,333$2.76$9.2K99,745Jul 1, 2026Jul 2, 2026View →
SEPN
SEPTERNA, INC.
SALE10b5-1
10b5-1 plan
2,100$34.10$71.6K97,645Jul 1, 2026Jul 2, 2026View →
SEPN
SEPTERNA, INC.
SALE10b5-1
10b5-1 plan
1,233$34.81$42.9K96,412Jul 1, 2026Jul 2, 2026View →
SEPN
SEPTERNA, INC.
PURCHASE
SVP, Drug Discovery
10,529$2.76$29.1K106,941Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
SALE
SVP, Drug Discovery
4,47125,529Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
SALE10b5-1
10b5-1 plan
7,000$35.97$251.8K96,412Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
PURCHASE
SVP, Drug Discovery
4,471$11.70$52.3K111,412Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
SALE
SVP, Drug Discovery
10,52910,376Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
SALE10b5-1
10b5-1 plan
8,000$35.10$280.8K103,412Jun 22, 2026Jun 24, 2026View →
SEPN
SEPTERNA, INC.
PURCHASEGRANT
Stock grant
80,00080,000Feb 6, 2026Feb 10, 2026View →
SEPN
SEPTERNA, INC.
SALE
SVP, Drug Discovery
3,501$18.06$63.2K92,911Nov 10, 2025Nov 13, 2025View →
SEPN
SEPTERNA, INC.
PURCHASEGRANT
Stock grant
30,00030,000Aug 7, 2025Aug 11, 2025View →
Other insiders · SEPN
Loading peer insiders…
About this filer
CIK 0002040349
ROLE
SVP, Drug Discovery
PRIMARY
SEPN
COMPANIES
1
ACTIVE SINCE
Aug 2025
MARKETPEEL · /INSIDER/0002040349DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback